Zelira Therapeutics Ltd. announce that its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment is now fully enrolled. No serious adverse events from dosing patients have been reported to date. Dosing is expected to be completed by April 2020 with the final report to be provided by mid 2020. Prescription opioids for treating chronic pain are linked to serious side effects including physical dependence, which is an acknowledged growing global crisis. In the United States an estimated 49,000 people died from opioid overdose in 2017. The Phase I trial is evaluating the safety and tolerability of whole plant extract following single and repeated doses with escalation in patients with chronic non-cancer pain on long-term opioid analgesia. Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trail. The trial is being undertaken at the St Vincent's Hospital in Melbourne in conjunction with Emerald Clinics Ltd. in Perth who were recently engaged as a second site.